Targeted Solutions for Viral Diseases

Novel antiviral therapeutics for the treatment of serious and/or chronic viral diseases including hepatitis C, influenza and norovirus.

View Product Pipeline

About Us

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses.

Learn More

Technology

We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

Learn More

Development Programs

Our development programs include a wide variety of serious and/or chronic viral diseases including hepatitis C, influenza and norovirus.

Learn More
Program Discovery Preclinical Phase 1 Phase 2a Phase 3
Hepatitis C CC-31244 - University of MD
(Pan-genotypic NS5B NNI)
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase in progress
Phase 3 Phase not started
Hepatitis C CC-31244 - Hong Kong
(Pan-genotypic NS5B NNI)
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase in progress
Phase 3 Phase not started
Influenza CC-42344
(Influenza A PB2 Inhibitor)
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started
Influenza Influenza A/B Inhibitor
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started
Norovirus Noro Polymerase Inhibitor
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started

Investor Presentation

View our latest Corporate Presentation

View Presentation View Fact Sheet

CEO Interview

Gary Wilcox, Ph.D., Chairman and CEO provides background on Cocrystal and the Company's innovative and Nobel Prize winning expertise during Facebook Live interview at Nasdaq Market Site.